Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
June 23, 2019 17:30 ET
|
Minerva Neurosciences, Inc
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific...
Major New Digital CBT Study Links Better Sleep To Better Overall Health
September 25, 2018 11:00 ET
|
Big Health
SAN FRANCISCO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Digital programs for improving sleep may improve overall health as well, according to new research published in JAMA Psychiatry. In a year-long...
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
December 06, 2017 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing
August 25, 2017 09:30 ET
|
Blake Insomnia Therapeutics, Inc.
NEW YORK, Aug. 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is...
Blake Insomnia Therapeutics Inc. Announces Appointment of Morten Albrechtsen to its Board of Directors
June 16, 2017 09:00 ET
|
Blake Insomnia Therapeutics, Inc.
NEW YORK, June 16, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is...
Minerva Announces Amended Agreement for MIN-202 in Insomnia
May 31, 2017 16:05 ET
|
Minerva Neurosciences, Inc.
Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by...
Blake Insomnia Therapeutics Inc. Announces Appointment of Kyle Sarwal and Ajit Johal to its Board of Directors
May 25, 2017 06:57 ET
|
Blake Insomnia Therapeutics, Inc.
NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Kyle Sarwal and Ajit Johal...
Blake Insomnia Therapeutics and Sajo Consulting Introduce Clinical Trial Team Members
March 02, 2017 09:49 ET
|
Blake Insomnia Therapeutics, Inc.
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to introduce the team appointed to conduct clinical trials of its...
Blake Insomnia Therapeutics Inc. Closes Joint Venture with Sajo Consulting LLC
February 24, 2017 20:08 ET
|
Blake Insomnia Therapeutics, Inc.
NEW YORK, Feb. 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce completion of a joint venture agreement for the development...
Blake Insomnia Therapeutics Inc. enters a joint development with Sajo Consulting LLC
February 08, 2017 16:54 ET
|
Blake Insomnia Therapeutics, Inc.
NEW YORK, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce entry into a Letter of Intent to provide joint development...